AAA
CERE

Affinity Asset Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Affinity Asset Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500,000
Closed -$20.4M – 112
2024
Q2 		$20.4M Buy
500,000
+200,000
+67% +$8.33M 2.36% 8
2024
Q1 		$12.7M Sell
300,000
-450,000
-60% -$18.9M 1.57% 19
2023
Q4 		$31.8M Buy
750,000
+64,939
+9% +$1.87M 5.81% 2
2023
Q3 		$15M Buy
685,061
+135,061
+25% +$3.38M 4.21% 5
2023
Q2 		$17.5M Buy
550,000
+170,000
+45% +$5.22M 6.11% 2
2023
Q1 		$9.27M Buy
380,000
+165,000
+77% +$4.84M 3.06% 8
2022
Q4 		$6.78M Buy
+215,000
New +$6.07M 2.66% 14
2022
Q2 		– Sell
-70,000
Closed -$2.45M – 71
2022
Q1 		$2.45M Sell
70,000
-155,000
-69% -$4.53M 0.39% 34
2021
Q4 		$7.29M Sell
225,000
-34,966
-13% -$1.23M 2.65% 14
2021
Q3 		$7.67M Buy
259,966
+59,966
+30% +$1.68M 1.94% 9
2021
Q2 		$5.12M Sell
200,000
-70,000
-26% -$1M 1.83% 17
2021
Q1 		$3.71M Hold
270,000
– – 1.26% 20
2020
Q4 		$4.48M Buy
+270,000
New +$3.51M 2.37% 10

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Affinity Asset Advisors's CERE Position: Q3 2024 in Review

Affinity Asset Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 500,000 shares — an estimated $20.4M sold.

Affinity Asset Advisors first reported a position in CERE in Q4 2020 and held it in 13 quarters. The position peaked at $31.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Affinity Asset Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 500,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $20.4M.
  • Affinity Asset Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • Affinity Asset Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $31.8M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.